Hoffmann-La Roche: Breast Neoplasms trials

The registry lists 229 Breast Neoplasms studies with Hoffmann-La Roche as lead sponsor. 17 are open to participants now and 123 have results posted.

Phase 1 38Phase 2 78Phase 3 63Phase 4 11No phase 52(a study in two phases counts in both)

Studies

Page 3 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Metastatic Breast Cancer (CRONOS 2)TerminatedNCT01277133
• Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast CancerCompletedNCT01254526Phase 1
• Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast CancerCompletedNCT01186991Phase 2
• A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)WithdrawnNCT01156961Phase 4
• A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With HerceptinCompletedNCT01152606
• A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast CancerCompletedNCT01142778Phase 2
• A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast CancerNo longer availableNCT01120561
• A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) ProgressionCompletedNCT01077726Phase 2
• A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast CancerWithdrawnNCT00964704Phase 2
• A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast CancerCompletedNCT00960960Phase 1
• Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based TherapyCompletedNCT00928330Phase 1
• A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast CancerCompletedNCT00882674Phase 1
• A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast CancerTerminatedNCT00845910Phase 2
• A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab EmtansineCompletedNCT00833963
• PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast CancerWithdrawnNCT00774241Phase 4
• A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast CancerCompletedNCT00773695Phase 2
• A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).CompletedNCT00661102Phase 3
• Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast CancerCompletedNCT00467012Phase 2
• A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast CancerCompletedNCT00337649Phase 1/2
• A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following ChemotherapyCompletedNCT00109265Phase 2
• A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast CancerCompletedNCT00109239Phase 3
• A Study of Patients With HER2-Positive Metastatic Breast CancerCompletedNCT00105456
• A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a TaxaneCompletedNCT00097487
• A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer StudyCompletedNCT00096967Phase 3
• A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast CancerTerminatedNCT00087620Phase 4
• Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone MetastasesCompletedNCT00060138Phase 1/2
• An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast CancerCompletedNCT00051779Phase 1
• Paclitaxel and Capecitabine in Treating Women With Metastatic Breast CancerCompletedNCT00005649Phase 2
• Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2CompletedNCT00005635Phase 2